BROOKSNSEBrooks Laboratories Limited· PharmaceuticalsMinimalNeutral
Announced Fri, 10 Apr · 17:20 IST

Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st March 2026.

BROOKS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.9%1-day move
₹72.00
prior close
₹71.05
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.5-0.9-1.1+0.6-1.9-3.5-6.8-9.7-11.8-10.6-25.0-33.3-5.6-2.9
Up moveDown movePending
AI summary

Brooks Laboratories has submitted a routine quarterly compliance certificate from its Registrar and Share Transfer Agent, MUFG Intime India Private Limited (formerly Link Intime), for the quarter ended 31st March 2026. The RTA confirms that all securities received for dematerialisation during the quarter were properly processed, with cancelled certificates mutilated and depository names recorded as the registered owners within prescribed timelines. Importantly, the filing notes that no requests for dematerialisation or rematerialisation were received during the entire quarter. This is a standard procedural submission required under SEBI's depository regulations, signed by the Company's Secretary & Compliance Officer, Krutika Rane, on 10th April 2026.

Likely market impact

This is a routine administrative filing with no material impact on shareholders or the stock price. It simply confirms that the company's share dematerialisation processes are functioning in compliance with SEBI regulations, with zero demat/remat activity in the quarter.